Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
IPO Year:
Exchange: AMEX
Website: actiniumpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2024 | $16.00 → $2.00 | Buy → Neutral | B. Riley Securities |
| 5/14/2024 | $25.00 | Overweight | Stephens |
| 9/6/2023 | $11.60 | Buy | HSBC Securities |
| 2/21/2023 | Outperform → Mkt Perform | William Blair | |
| 9/8/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 8/25/2022 | $16.00 | Buy | B. Riley Securities |
| 8/3/2021 | $57.00 → $45.00 | Buy | HC Wainwright & Co. |
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
DEF 14A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
SCHEDULE 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
3 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously
Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00
HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60
William Blair downgraded Actinum Pharma from Outperform to Mkt Perform
Cantor Fitzgerald initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $20.00
B. Riley Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $16.00
HC Wainwright & Co. reiterated coverage of Actinium Pharmaceuticals with a rating of Buy and set a new price target of $45.00 from $57.00 previously
HC Wainwright & Co. reiterated coverage of Actinium Pharmaceuticals with a rating of Buy and set a new price target of $57.00 from $65.00 previously
Fastest customizable press release news feed in the world
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations ATNM
New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide (Erleada®), and darolutamide (Nubeqa®)- directly targeting the point of failure for a high proportion of mCRPC patients ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumorsPlayed a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster statusLed clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life TechnologiesTimely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A,
Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidatesOptimized CAR improved tumor targeting, internalization, and pharmacokinetics of 225Ac-labeled antibodiesLower-CAR conjugates preserved tumor targeting while reducing off-target liver and spleen uptake, supporting a wider therapeutic window that may enable higher, safer dosingFindings reinforce Actinium's proprietary radiochemistry expertise and directly support the Company's broader radioconjugate pipeline a capability that applies to every program from the platformNEW YORK, June 1, 2026 /PRN
Together the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwideNEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Canadian Intellectual Property Office (CIPO) has issued Notices of Allowance for two patent applications spanning the Company's Actimab-A and Iomab-ACT programs. The allowances broaden Actinium's intellectual property protection across both hematologic malignancies and next-generation conditioning for gene-edited cell-based
NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400, highlighting new data that will be showcased across three presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. Two of the presentations showcase ATNM-400's differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third demonstrates the importance of radioconjuga
– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its development as a mutation-agnostic therapy in settings whereresistance to EGFR- and KRAS-targeted agents remains a major clinical challenge– ATNM-400 in prostate cancer: New data further supports ATNM-400 as a potentialtreatment option across the spectrum of PSMA-high, PSMA-low, and PSMA-negativedisease, addressing a key limitation of PSMA-targeted therapies – Radioconjugation platform: New data demonstrates that optimizing chelator-to-antibody ratio(CAR) improves tumor targeting, internalization, and pharmacokinetics of 225Ac-labeledantibodies, directly supporting ATNM-400 development and re
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potentialIn prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settingsIn EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab b
Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backboneTranscriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative
New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A demonstrates mutation-agnostic efficacy and a novel mechanism that enhances response to standard AML therapies Multiple data catalysts for ATNM-400 and Actimab-A in 2026; and posters for each to be presented on April 21, 2026 at AACR 2026 in San Diego, CANEW YORK, April 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be presented at the American Association for Cancer Re
This live feed shows all institutional transactions in real time.
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
Live Leadership Updates
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities. Actinium recently completed expansion of its New York City based research facilities to focus on the development of targeted radiotherapies for solid tumors and blood cancers and to investigate novel radiotherapy combinations with checkpoint inhibitors. Actinium has more than doubled its laboratory footprint and expanded its R&D capabilities. In addition to infrastructure, Actinium has increased its R&D team to include scientists with e
NEW YORK, March 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Mark Kubik, MBA to the position of Chief Business Officer (CBO). In this role, Mr. Kubik will be responsible for leading the Company's business development activities including collaboration and partnership activities as well as portfolio and alliance management. He will focus on leveraging Actinium's AWE technology platform, which encompasses Actinium's strong intellectual property portfolio, know-how and research capabilities, and pipeline of ARCs or antibody radiation conjugates to drive business development activity. Mark joins Actinium from OncoIm
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium's CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia ("R/R AML"). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to work
Live finance-specific insights
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm - In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients - Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 - Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover - Iomab-B was
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,
- Full Iomab-B SIERRA data set to be presented in late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 - Company to host conference call and webcast on Saturday, February 18, 2023, at 6:00 PM EST - SIERRA trial met primary endpoint with high statistical significance (p<0.0001) - Company to host Iomab-B KOL event with Dr. Sergio Giralt of Memorial Sloan Kettering Cancer Center at 8:00 AM EST on February 28, 2023 NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that data from its pivotal Phase 3 SIERRA trial of Iomab-B have been accepted as
- Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of <0.0001 NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was conducted in patients 55 years of age or older who had active disease (relapsed or refractory AML). The SIERRA trial is a randomized, multi-center, controlled study which compared Iomab-B as a
INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors. myNEXUS delivers integrated clinical support services for approximately 1.7 million Medicare Advantage members across 20 states. “Providing timely care for members in their homes allows for both excellent personalized care as well as the comfort of being in preferred environments,” said Prakash Patel, M.D., Anthem Executive Vice President, and President, Anthem Diversified Business Group. “Bringing the right level of whole person care into the home has been de